GlassScriptPhysician profile
Jeffry T Evans
NPI 1548249238
$5,038.84
in general payments reported to CMS, 2019-2025
32 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.13 · 2020: $136 · 2021: $235 · 2022: $974 · 2023: $1,223 · 2024: $1,261 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,604.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.08 | 2021-2025 | |
| Novo Nordisk INC | $692.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $595.49 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $415.28 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $358.01 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.88 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $269.08 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $213.60 | 2022-2024 | Xarelto |
| Lilly USA, LLC | $195.72 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Astellas Pharma US INC | $148.40 | 2022-2025 | Veozah |
| Pfizer INC. | $128.00 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $122.59 | 2021-2022 | |
| Boston Scientific Corporation | $98.97 | 2022-2025 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $88.71 | 2022-2025 | Rexulti |
| Edwards Lifesciences Corporation | $82.50 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $81.79 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $61.56 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $44.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.73 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $38.30 | 2024 | Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $33.53 | 2025 | |
| Sunovion Pharmaceuticals INC. | $31.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $30.40 | 2022-2023 | |
| Exact Sciences Corporation | $29.52 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.05 | 2025 | Caplyta |
| Mylan Specialty L.P. | $19.35 | 2023 | Yupelri |
| Verona Pharma, INC. | $19.32 | 2025 | Ohtuvayre |
| Exeltis, USA INC. | $14.90 | 2023 | Slynd |
| Esperion Therapeutics, INC. | $14.90 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2022 | |
| Merck Sharp & Dohme LLC | $13.84 | 2025 | Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffry Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.